Meet Monica Loghin, M.D.
Monica E. Loghin, M. D.
Department of Neuro-Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1983 | "Gr.T. Popa" University of Medicine and Pharmacy, Iasi, RO, MD |
Postgraduate Training
| 2003-2005 | Clinical Fellowship, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2000-2003 | Clinical Residency, Neurology, UT Health Science Center, Houston, Texas |
| 1999-2000 | Clinical Residency, Internal Medicine, UT Health Science Center, Houston, Texas |
| 1998-1999 | Observer, Neurology, UT Health Science Center, Houston, Texas |
| 1990-1998 | Assistant Professor, Neurology, Hospital #3, Neurology and Neurosurgery, Iasi |
| 1988-1990 | Clinical Residency, Neurology, University of Medicine and Pharmacy, Iasi |
| 1986-1988 | Family practitioner, Family practice, Directia Sanitara Judeteana Iasi, Iasi |
| 1983-1986 | General Medicine Training, Medicine, Directia Sanitara Judeteana Iasi, Iasi |
Licenses & Certifications
| 2015 | United Council for Neurologic Subspecialties |
| 2006 | Texas Medical License |
| 2005 | The American Board of Psychiatry & Neurology |
Experience & Service
Administrative Appointments/Responsibilities
Co-Faculty Liaison, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Section Chief, Cancer Neurology Section, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Clerkship Rotation Site Program Director, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Residency Rotation Site Program Director, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Extramural Institutional Committee Activities
Member, Oncology Fund of Knowledge Exam Review, The University of Texas MD Anderson Cancer Center, 2018 - 2019
Member, Credentials Committee of the Medical Staff (CCMS), The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, CARTOX Cell Therapy Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Spinal Cord Compression Management Algorithm, The University of Texas MD Anderson Cancer Center, 2014 - Present
Member, Acute Ischemic Stroke Clinical Effectiveness Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present
Alternate Member, Credentials Committee of the Medical Staff (CCMS), The University of Texas MD Anderson Cancer Center, 2013 - 2013
Member, Pain Medicine Search Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2013
Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2007 - Present
Member, Graduate Medical Education Institutional Review Subcommittee, The University of Texas MD Anderson Cancer Center, 2007 - 2015
Member, Clinical Research Committee 3, The University of Texas MD Anderson Cancer Center, 2007 - 2010
Honors & Awards
| 2026 - Present | Nominated for Gerald P. Bodey Award for Excellence in Education, The University of Texas MD Anderson Cancer Center |
| 2024 - 2025 | Nominated for Gerald P. Bodey Award for Excellence in Education, The University of Texas MD Anderson Cancer Center |
| 2020 - 2021 | Nominated for Gerald P. Bodey Award for Excellence in Education, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
| 2013 - 2014 | Nominated for Gerald P. Bodey Award for Excellence in Education, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
| 2011 - 2012 | Nominated for Gerald P. Bodey Award for Excellence in Education, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Cancer Neurology: What have we learned and where are we going?. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2024. Cancer Neurology: What have we learned and where are we going?. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2022. Immunotherapy Induced Neurotoxicity. Conference. Baylor College of Medicine. Houston, TX, US.
- 2019. Neurotoxicity. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Understanding and Managing Treatment Related Complications. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2022. Neurotoxicity. Conference. The University of Texas Medical Branch - Galveston. Galveston, TX, US.
National Presentations
- 2023. Outcomes of patients with neoplastic meningitis undergoing ventriculoperitoneal shunting and intrathecal chemotherapy, a single institution retrospective review study. Invited. American Academy of Neurology. Boston, MA, US.
- 2018. Gliomatosis Cerebri: Potential Biological Predictors of Tumor Migrational Patterns. Conference. American Academy of Neurology (AAN). Los Angeles, CA, US.
International Presentations
- 2026. Immunotherapy induced neurotoxicity. Invited. 5th SeENS International Neurosurgical Course. Cluj-Napoca, RO.
- 2025. Neurological Complications of Cancer Therapy: Approaches to diagnosis and management. Invited. The Medical Days of the Moinesti Municipal Emergency Hospital, 20th Edition. Moinesti, RO.
- 2024. Unique Presentations of Cancer and Cancer Therapy. Invited. The Medical Days of the Moinesti Municipal Emergency Hospital, 19th Edition. Moinesti, RO.
- 2024. Outcome of Patients with Neoplastic Meningitis Undergoing Ventriculoperitoneal Shunt and Intrathecal Chemotherapy, A Single Institution Retrospective Review. Poster. 10th Congress of the European Academy of Neurology (EAN). Helsinki, FI.
- 2022. Neurological Complications of Liver Transplantation. Invited. ROMTRANSPALNT Congress, 2022 edition. Bucharest, RO.
- 2019. New Insights into Neurologic Complications in Liver Transplantation. Invited. National Congress of the Romanian Association of Hepato-Bilio-Pancreatic Surgery And Liver Transplantation. Iasi, RO.
- 2019. Immunotherapy (CAR T cell and immune checkpoint inhibitors) Induced Neurotoxicity. Invited. 2019 Updates in Oncology Conference. Iasi, RO.
- 2019. Multidisciplinary Management of Brain Metastases in Non Small Cell Lung Carcinoma. Invited. People's Republic of China, The Medical Association of Fuzhou City. Fuzhon, CN.
- 2016. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. Conference. American Academy of Neurology. Vancouver, CA.
- 2016. Gliomatosis, to be or not to cerebri?. Conference. American Academy of Neurology (AAN). Vancouver, CA.
Formal Peers
- 2014. Leptomeningeal Disease: The Orphan Child. Invited. Galveston, TX, US.
Grant & Contract Support
| Date: | 2007 - 2011 |
| Title: | Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| ID: | 1 R01 NR009675-01A2 |
Selected Publications
Peer-Reviewed Articles
- Yeboa, DN, Whitfield, BT, Lin, R, Ejezie, CL, Swanson, T, Beckham, TH, Wang, C, De, BS, Perni, S, Tom, MC, Li, J, McGovern, SL, Harrison, R, Majd, NK, Puduvalli, VK, Aaroe, AE, Loghin, ME, O'Brien, BJ, Patel, AD, Patel, C, Wefel, JS, Taslicay, CA, Gule-Monroe, MK, Paulino, AC, McAleer, MF, Grosshans, DR, Ghia, AJ, Jiang, W, Chung, C, Maor, MM, Yang, CH, Gubbiotti, M, Kamiya Matsuoka, C, Ballester, L, Weathers, S, Huse, J. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses. Journal of neuro-oncology 176(1), 2026. e-Pub 2026. PMID: 41191157.
- Weathers, S, Li, X, Zhu, H, Damania, A, Knafl, M, McKinley, BA, Lin, Y, Harrison, R, Majd, NK, O’Brien, BJ, Penas-Prado, M, Loghin, ME, Kamiya-Matsuoka, C, Yung, WA, Solis Soto, LM, Maru, DM, Wistuba, II, Parra Cuentas, ER, Hernandez, S, Futreal, A, Wargo, J, Schulze, K, Darbonne, WC, Ajami, NJ, Woodman, SE, de Groot, JF. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40289138.
- Faraj, CA, McCutcheon, IE, Gubbiotti, M, Perni, S, Gule-Monroe, MK, Akdemir, KC, Clark, VE, Bander, ED, Loghin, ME, Prabhu, SS, Lang Jr, FF, Weinberg, J. Extra-central nervous system metastasis from high-grade glioma. Journal of neuro-oncology 173(1):193-204, 2025. e-Pub 2025. PMID: 40055259.
- Lam, K, Nasr, L, Andersen, C, Marqueen, KE, Li, J, Wang, C, Beckham, TH, Majd, NK, Aaroe, AE, Loghin, ME, O'Brien, BJ, McGovern, SL. Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors. Advances in Radiation Oncology 10(2), 2025. e-Pub 2025. PMID: 39866593.
- Gregory TA, Knight SR, Aaroe AE, Highsmith KN, Janatpour ZC, O'Brien BJ, Majd NK, Loghin ME, Patel CB, Weathers SP, Puduvalli VK, Kamiya-Matsuoka C. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study. Neurooncol Pract 11(4):475-483, 2024. e-Pub 2024. PMID: 39006516.
- Simbaqueba C, Aaroe A, Rubio D, Loghin ME, Treiber J, Ballester L, Fuller G, Gopakumar S, Kim B, Suarez-Almazor M. Leptomeningeal Immunoglobulin G4–Related Disease: A Case Report. AIM Clinical Cases 2(e230907), 2023. e-Pub 2023.
- Robertson IJ, Gregory TA, Loghin ME. Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab. Annals of Case Reports(8):1331, 2023. e-Pub 2023.
- Robertson IJ, Gregory TA, Loghin ME. Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab. Ann Case Report 8(3), 2023. e-Pub 2023.
- Simbaqueba Clavijo, CA, Aaroe, AE, Rubio, D, Loghin, ME, Treiber, J, Ballester, L, Fuller, GN, Gopakumar, S, Kim, BY, Suarez-Almazor, M. Leptomeningeal Immunoglobulin G4–Related Disease. Annals of Internal Medicine Clinical Cases 2(12), 2023. e-Pub 2023.
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
- Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SL. Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv 4(1):vdac129, 2022. e-Pub 2022. PMID: 36128585.
- de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22(4):539-549, 2020. e-Pub 2020. PMID: 31755915.
Review Articles
- Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol 15:1447021, 2024. e-Pub 2024. PMID: 39247203.
Other Articles
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. PMID: 38965214.
- Robertson IJ, Gregory TA, Loghin ME Remission of Her2neu Amplified Breast Carcinoma Involving Brain and Leptomeninges with Concurrent Disappearance of Her2neu Amplified Circulating Tumor Cells Following Intrathecal and Systemic Delivery of Trastuzumab. Annals of Case Reports, 2023.
Abstracts
- Kamiya Matsuoka, C, Weathers, SP, Yung, A, Loghin ME, Majd, N, Brown, D, Langlands, J, Schwartz, R, Knight, S, Puduvalli, VK, de Groot, JF, O'Brien, BJ. Assessment of molecular alterations in newly diagnosed GBM MGMT-unmethylated patients treated with VAL-083. 29th Meeting of the Society for Neuro-Oncology (SNO) 26(Suppl_8):viii114, 2024. e-Pub 2024.
- Lam, K, Nasr, L, Andersen, C, Marqueen, K, Li, J, Wang, C, Majd, N, Aaroe, AE, Loghin ME, McGovern, S, O'Brien, BJ. Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis from Solid Tumors. 29th Annual Meeting of the Society for Neuro-Oncology (SNO) 26(Suppl_8):viii74-viii75, 2024. e-Pub 2024.
- Weathers S, Kamiya Matsuoka C, Majd N, Ashu A, Thompson C, Gachimova, Aaroe A, Patel C, Loghin M, O'Brien B, Yung WKA, Puduvalli VK, de Groot J. Safety run-in results of a phase I/II study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma. Neuro-Oncology 25(Suppl_5):v67, 2023. e-Pub 2023.
- Majd N, Yeboa N, Weathers S, Robichaux C, Al Ansari H, Gachimova E, Loghin M, Kamiya Matsuoka C, O"Brien B, Aaroe A, Patel C, Yung A, Puduvalli V, de Groot J. Phase I clinical trial of peposertib plus radiation in newly diagnosed MGMT-unmethylated glioblastoma. Neuro-Oncology 25(Suppl_5):v84, 2023. e-Pub 2023.
- Kamiya Matsuoka C, Weathers S, Yung A, Loghin M, Majd N, Brown D, Langlands J, Schwartz R, Knight S, de Groot J, Puduvalli V, O'Brien B. Evaluation of post-progression treatments after VAL-083 in recurrent and newly diagnosed GBM MGMT unmethylated patients. Neuro-Oncology 25(Suppl_5):v95-v96, 2023. e-Pub 2023.
- Gottiparthy A, Orda-Nguyen L, Morrow E, Loghin ME. Outcomes of Patients with Neoplastic Meningitis Undergoing Ventriculoperitoneal Shunting and Intrathecal Chemotherapy. A single institution retrospective review. Poster Presentation, 2023 Annual Meeting of the American Academy of Neurology, 2023. e-Pub 2023.
- Gregory T, Loghin M. Case report: extended remission of HER2-positive breast carcinoma with brain metastases and leptomeningeal disease following intrathecal and systemic trastuzumab. Neuro-Oncology 24(Suppl_7):vii198, 2022. e-Pub 2022.
- Amer A, Darbandi AD, Wang EB, Ciavarra BN, Lano KR, Krayyem A, Alhasan HR, Fuller GR, Ferguson SD, Loghin ME, Li J, McGovern SL, Johnson JM. Clinical and pathologic characteristics of long-term glioblastoma survivors. 2022 ASCO Annual Meeting 40(Number 16_Suppl), 2022. e-Pub 2022.
- Weathers SS, Zhu H, Knafl M, Damania A, Kamiya-Matsuoka C, Harrison RA, Lyons L, Yun C, Darbonne WC, Loghin ME, Penas-Prado M, Majd N, Yung WKA, O'Brien BJ, Wistuba II, Futreal A, Wargo JA, Ajami NJ, Woodman SE, de Groot JF. Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation. 2022 ASCO Annual Meeting 40(Number 16_Suppl), 2022. e-Pub 2022.
- Weathers SP, Knafl M, Parra E, Hernandez S, Solis L, Sanchez Espiridion B, Wistuba I, Futreal A, Maru D, Kamya-Matsuoka C, Harrison R, Joseph V, Yun C, Darbonne W, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, Woodman S, de Groot J. Biomarker Immune Correlates in Newly Diagnosed Glioblastoma (GBM) Treated with Atezolizumab in Combination with Temozolomide (TMZ) and Radiation. Neuro-Oncology 23(Suppl_6):vi49, 2021. e-Pub 2021.
- O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers S, Yung WKA, Loghin M, Harrison R, Majd N, Knight S, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, An S, Lopez L, de Groot J. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-unmethylated, Bevacizumab-Naive Glioblastoma in the Recurrent and Adjuvant Setting. Neuro-Oncology 23(Suppl_6):vi65, 2021. e-Pub 2021.
- Aaroe AA, Alfaro-Munoa KD, Bornstein C, Kell T, Camp S, Chen M, Woodman K, Tummala S, Kleiman A, de Groot JF, Loghin ME. A Retrospective Single-Center Experience with Nonbacterial Thrombotic Endocarditis and Stroke - Outcomes, Anticoagulation Strategies, and Incorporation of Next-Generation Sequencing Data. Neuro-Oncology 22((suppl 2)):ii127, 2020. e-Pub 2020.
- Aaroe AA, Dono A, Youssef M, Alfaro-Munoz K, Weathers S, O’Brien BJ, Majd N, Harrison RA, Loghin ME, Soomro Z, Williford G, Fuller G, Yung WK, Yeboa D, Esquenazi, Ballester LY, de Groot JF, Kamiya Matsuoka C. A Retrospective Study of Treatment Strategies and Outcomes in WHO Grade II and III Isocitrate Dehydrogenase (IDH) Wild-Type Astrocytoma. Neuro-Oncology 22((suppl 2)):ii164-ii165, 2020. e-Pub 2020.
- Aaroe A, Team D, Harrison R, Majd N, O’Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WKA, de Groot J, Woodman K. A Snapshot of the Impact of COVID-19 on Patients with Nervous System Tumors. Neuro-Oncology 22((suppl 2)):ii27, 2020. e-Pub 2020.
- Weathers SP, Kamiya-Matsuoka C, Harrison R, Liu D, Sanqui, Dervin S, Yun C, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, de Groot J. Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Neuro-Oncology 22((suppl 2)):ii35, 2020. e-Pub 2020.
- O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, de Groot J. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-Unmethylated, Bevacizumab-Naive Glioblastoma in the Recurrent and Adjuvant Setting. Neuro-Oncology 22((suppl 2)):ii59, 2020. e-Pub 2020.
- Youssef MN, Pham LC, Demirhan M, Harrison RA, Loghin ME, Johnson JK, Alfaro-Munoz KD, Bhat KP, Yeboa D, Prabhu SS, Raza S, de gRoot JF, Demonte F, Kamiya-Matsuoka C. Long-Term Use of Everolimus plus Octreotide for Recurrent Intracranial or Spinal Meningioma: A Single Institution Experience. Neuro-Oncology 22((suppl 2)):ii55, 2020. e-Pub 2020.
- Weathers S, Kamiya Matsuoka C, Harrison RA, Liu DD, Dervin S, Yun C, Loghin ME, Penas-Prado M, Majd N, Yung WK, O’Brian BJ, de Groot JF. Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Journal of Clinical Oncology 38(suppl_15), 2020. e-Pub 2020.
- O'Brien B, Penas-Prado M, Kamiya C, Weathers SP, Yung WK, Loghin M, Harrison RA, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, de Groot JF. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro-Oncology 21(suppl_6):vi14-vi15, 2019. e-Pub 2019.
- Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot J, O'Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Neuro-Oncology Advances 1(suppl_1):i8, 2019. e-Pub 2019.
- Kamiya Matsuoka C, Metrus N, Weathers S, Ross J, Shaw KR, Penas-prado M, Loghin ME, Alfaro-Munoz K, O'Brien BJ, Harrison R, Sadighi Z, Majd N, Yung WK, Meric-Bernstam F, Hambardzumyan D, de Groot J. Is Immuno-Oncology Therapy Effective in Hypermutator Glioblastomas with Somatic or Germline Mutations?. Annals of Oncology 30(suppl_5):v143-v158, 2019. e-Pub 2019.
- Weathers S, Kamiya-Matsuoka C, Dervin S, Yun C, Loghin M, O'Brien B, Harrison R, Yung WK, Penas-Prado M, de Groot J. Safety Run-In Results for a Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Neuro-Oncology 20(suppl_6):vi9–vi10, 2018. e-Pub 2018.
- Metrus N, Daher A, Harrison R, Majd N, Maraka S, Nam J, Trevino C, Weathers S, O'Brien B, Kamiya-Matsuoka C, Loghin M, Alfaro K, Hunter K, Yung WK, de Groot J, Penas-Prado M. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Neuro-Oncology 20(suppl_6):vi141, 2018. e-Pub 2018.
- Penas-Prado M, Weathers S, Zhou S, Kamiya-Matsuoka C, O'Brien B, Loghin M, Harrison R, Pei B, Ictech S, Hunter K, Yung WK, de Groot J, Shpall EJ, Heimberger A, Rezvani K. A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells (CMV-TC) for Glioblastoma: Dose Escalation and Correlative Results. Neuro-Oncology 20(suppl_6):vi2–vi3, 2018. e-Pub 2018.
- de Groot J, Penas-Prado M, Mandel J, O'Brien B, Weathers S, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse J, Rao G, Weinberg J, Prabhu S, Ferguson S, Yuan Y, Vence L, Allison J, Sharma P, Heimberger A. Window-of-Opportunity Clinical Trial of Pembrolizumab in Recurrent Glioblastoma Patients. Neuro-Oncology 20(suppl_6):vi2, 2018. e-Pub 2018.
- Kamiya Matsuoka C, Metrus NR, Shaw KR, Penas-Prado M, Weathers, SS, Loghin ME, Alfaro-Munoz K, Yuan Y, O'Brien BJ, Harrison, RA, Yung, WK, Meric-Bernstam F, Groot D, JF. The Natural Course of Hypermutator Gliomas. Journal of Clinical Oncology 36(suppl), 2018. e-Pub 2018.
Book Chapters
- Majd NK, Loghin M. Leptomeningeal Disease in Solid Cancers. In: Oncologic Critical Care. Springer, Cham, 2019.
- Loghin M, Kleiman A. Medication-Induced Neurotoxicity in Critically Ill Cancer Patients. In: Oncologic Critical Care. Springer, Cham, 2019.
Patient Reviews
CV information above last modified April 01, 2026